Novel practical approaches taken within drug discovery and delivery of CNS therapeutics
London (PRWEB UK) 19 August 2013 -- The highly anticipated and respected 12th annual Clinical Trials in CNS conference is coming to London on 18th & 19th November 2013. With an ever increasing average life expectancy neurodegenerative diseases are increasingly becoming more prevalent in society; this results in an increased need for new and improved therapies for treating these neurodegenerative conditions. From Alzheimer's to Parkinson's disease the target and mechanism by which a disease manifests is unique and presents challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.
Clinical Trials in CNS is a two day content packed agenda featuring new approaches taken in this field towards a number of neurodegenerative disorders, from clinical trial modelling and simulation to the role of biomarkers. The agenda presents a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This innovative conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices to design late stage clinical trials, the importance of understanding the pathophysiology and biology of disease processes with use of biomarkers and imaging techniques. The event also provides an overview of how to overcome challenges of delivery within the CNS.
Keynote speaker will include Johannes Streffer, Director of Experimental Medicine Europe, Neurologist, Johnson & Johnson, who will give a presentation on Translational Medicine Models in Neurodegenerative diseases looking at continuous CSF measurements: Indwelling CSF catheters for monitoring CNS effects.
The conference will also feature presentation on early detection of Alzheimer's Disease in Mid-life lead by Craig Ritchie, Clinical Senior Lecturer, Imperial College London, highlighting pathological changes in mid-life which lead to dementia in older people and outline UK-based infrastructure initiatives to support translational medicine innovations in dementia research around mid-life and early dementia.
Attendees can also attend a half day workshop held on 20th November which will be on: Defining Clinical Relevance. Led by QCTR, the workshop will examine how to develop a better awareness of the limitations of primary outcome measures in neurological diseases and how to select and make a case to regulatory authorities for a single efficacy outcome measure.
Sponsors for the event will also include: Bracket, Cytox, Hermo Pharma & QCTR
For the full conference programme and further information please visit:
http://www.smi-online.co.uk/goto/clinicaltrialscns54.asp for more information
or Contact Jonathan Collins on +44 (0)20 7827 6734 or email: jcollins(at)smi-online(dot)co(dot)uk
Sponsorship opportunities are available for this event, please contact Alia Malick on +44(0) 20 7827 6168.
Contact for media-partners: Margaret Mugema, mmugema(at)smi-online(dot)co(dot)uk, +44 (0) 20 7827 6072
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
For more information, please visit http://www.smi-online.co.uk .
Margaret Mugema, SMi Group Ltd, http://www.smi-online.co.uk/goto/clinicaltrialscns54.asp, +44 2078276072, [email protected]
Share this article